PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Highest French Court Rules Killer of Jewish Woman Cannot Stand Trial

Show Me

Michigan: ‘Strongest public health order in the Midwest’ now requires masks for 2-year-olds

Show Me

Maryland adds 1,500 COVID cases while positivity ticks up, hospitalizations decline

Show Me

Worldwide COVID-19 death toll tops 3 million

Show Me

US Army Prepares for Possible Global Land Conflict with China

Show Me

Bannon’s War Room | Saturday Edition | Recorded April 17, 2021 | Video: 48 Minutes 49 Seconds

Show Me

U.S. Intel Walks Back Claim Russians Put Bounties on American Troops

Show Me

‘Mysterious headless beast’ spotted in a tree in Poland turns out to be a CROISSANT

Show Me

Schiff and Swalwell Went All in on the Dubious Russia Bounty Story

Show Me

Progressive group ramps up pressure on Justice Breyer to retire

Show Me

Trump Ally Vernon Jones Announces Run for Georgia Governor

Show Me

Most Colorado counties loosened COVID-19 restrictions Friday, despite rising hospitalizations

Show Me

How a podcast helped police find alleged killer of California student gone missing in 1996

Show Me

Alleged sex trafficking victim may be cooperating with feds in Matt Gaetz investigation, ex-girlfriend says

Show Me

The Justice Department sues Roger Stone, a longtime Trump ally, alleging tax evasion.

Show Me

Lance Armstrong stands by son accused of sexual assault

Show Me

White House: Ambassador won’t be punished for publicly linking U.S. founding to ‘white supremacy’

Show Me

April 16, 2021 | Nightly News Rebroadcast | Video: 54 Minutes 48 Seconds

Show Me

April 16, 2021 | Nightly News Rebroadcast | Video: 54 Minutes 48 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded April 16, 2021 | Video: 48 Minutes 27 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded April 16, 2021 | Video: 48 Minutes 49 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded April 15, 2021 | Video: 48 Minutes 59 Seconds

Show Me

SolarWinds hack got emails of top DHS officials, AP sources say

Show Me

Multiple people shot at FedEx facility in Indianapolis

Show Me

(CENSORED) James O’Keefe of Project Veritas

Show Me

Fox News hires high-profile defense team in Dominion defamation lawsuit

Show Me

Facebook Faces Formal Irish Privacy Probe Into Data Leak

Show Me

Mike Lindell: Free, Clean Speech Social Media Site Set to Launch Monday

Show Me

YouTube Suspends Rebel News over ‘Election Misinformation’

Show Me

Kristen Clarke, Bigot and Liar

Show Me

Border Agents Report Being Overworked, Understaffed And Exposed To COVID-19 During Migrant Surge

Show Me

Sub-Saharan Africa: The devastating impact of conflicts compounded by COVID-19 

Show Me

Texas Ranchers Dealing With Armed Smugglers on Land

Show Me

Trump-supporting ex-Democrat Vernon Jones to run against Gov. Kemp in Georgia GOP primary

Show Me

Jimmy Lai, Martin Lee, Among 10 HK Dissidents to Be Sentenced Over Outlawed Pro-Democracy Protest

Show Me

Facebook’s Oversight Board Will Remove Posts Flagged By Users

Show Me

BBC Diversity Chief Declares Idris Elba Character Not Black Enough to Be ‘Authentic’

Show Me

Chelsea Clinton calls on Facebook to ban Tucker Carlson

Show Me

BREAKING: Facebook Blocks New York Post Story About BLM Founder Spending Millions On Luxury Homes

Show Me

April 15, 2021 | Nightly News Rebroadcast | Video: 49 Minutes 02 Seconds

Show Me